Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ADC Therapeutics
Biotech
ADC Therapeutics axes lead solid tumor drug after phase 1 blow
The biotech axed the AXL-directed antibody-drug conjugate after failing to show a favorable benefit-risk profile in a phase 1b trial.
Nick Paul Taylor
Nov 7, 2024 8:24am
ADC Tx, Aldeyra leave programs behind in 2023
Jan 4, 2024 10:05am
ADC Therapeutics calls it quits on Adagene solid tumor collab
Aug 31, 2023 10:24am
ADC implements 'lower risk' strategy of layoffs, pipeline culls
May 9, 2023 9:50am
New year, new C-suite execs—Chutes & Ladders
Jan 6, 2023 9:30am
ADC therapy sidelined after FDA nixes accelerated review chance
Nov 8, 2022 10:25am
